Briefing
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
The phase 3 CALLA trial of durvalumab plus chemoradiotherapy versus chemoradiotherapy alone in 770 women with locally advanced cervical cancer did not significantly improve investigator-assessed PFS in a biomarker-unselected population (HR 0.84, 95% CI 0.65–1.08, P=0.17).
- Design: Evidence level 2
- Assay: Not named in the abstract
Lancet OncolPubMed 38039991DOI 10.1016/S1470-2045(23)00479-5